Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
Antiepileptic Drugs: Sodium Channel Blockers01:08

Antiepileptic Drugs: Sodium Channel Blockers

Antiepileptic drugs are specialized medications that prevent seizures in individuals diagnosed with epilepsy. These drugs primarily function by blocking the movement of sodium ions through channels in the neuronal membrane, inhibiting the repetitive firing of action potentials often associated with seizures.
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Antiepileptic Drugs: Calcium Channel Blockers01:17

Antiepileptic Drugs: Calcium Channel Blockers

Calcium channel blockers, a class of antiepileptic drugs, regulate the flow of calcium ions within neurons.
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cortical stimulation reveals effective disconnection of the epileptogenic network at seizure onset.

Epilepsia·2026
Same author

Association between Interictal Spike Rate and Seizure Frequency in a Large Epilepsy Cohort.

medRxiv : the preprint server for health sciences·2026
Same author

The Physics and Physiology of Electrical Stimulation of the Brain.

Journal of clinical neurophysiology : official publication of the American Electroencephalographic Society·2026
Same author

The seizure embedding map: a spatio-temporal transformer for comparing patients by ictal intracranial EEG features at scale.

Journal of neural engineering·2026
Same author

Regional excitability, not epileptic pathology, drives stimulation-evoked interictal spike increases.

medRxiv : the preprint server for health sciences·2026
Same author

How Much Does the Reduced EEG Montage Matter for Seizure Detection?: A Large-Cohort Simulation Study.

medRxiv : the preprint server for health sciences·2026

Related Experiment Video

Updated: May 15, 2026

Electrophoretic Delivery of γ-aminobutyric Acid (GABA) into Epileptic Focus Prevents Seizures in Mice
07:01

Electrophoretic Delivery of γ-aminobutyric Acid (GABA) into Epileptic Focus Prevents Seizures in Mice

Published on: May 16, 2019

Optimizing Antiseizure Medication Taper in the Epilepsy Monitoring Unit.

Kerry C Nix1,2, Nina J Ghosn2,3, Kevin Xie2,3

  • 1Department of Neuroscience, Perelman School of Medicine, University of Pennsylvania, Philadelphia.

Neurology. Clinical Practice
|May 13, 2026
PubMed
Summary

Optimizing antiseizure medication (ASM) tapering in epilepsy monitoring units (EMUs) can safely precipitate seizures. Rapid tapering to 50% baseline ASM load may improve diagnostic yield without increasing seizure risk in certain patients.

More Related Videos

Stereo-Electro-Encephalo-Graphy (SEEG) With Robotic Assistance in the Presurgical Evaluation of Medical Refractory Epilepsy: A Technical Note
05:54

Stereo-Electro-Encephalo-Graphy (SEEG) With Robotic Assistance in the Presurgical Evaluation of Medical Refractory Epilepsy: A Technical Note

Published on: June 13, 2016

Sampling Cerebrospinal Fluid and Blood from Lateral Tail Vein in Rats During EEG Recordings
10:46

Sampling Cerebrospinal Fluid and Blood from Lateral Tail Vein in Rats During EEG Recordings

Published on: September 1, 2023

Related Experiment Videos

Last Updated: May 15, 2026

Electrophoretic Delivery of γ-aminobutyric Acid (GABA) into Epileptic Focus Prevents Seizures in Mice
07:01

Electrophoretic Delivery of γ-aminobutyric Acid (GABA) into Epileptic Focus Prevents Seizures in Mice

Published on: May 16, 2019

Stereo-Electro-Encephalo-Graphy (SEEG) With Robotic Assistance in the Presurgical Evaluation of Medical Refractory Epilepsy: A Technical Note
05:54

Stereo-Electro-Encephalo-Graphy (SEEG) With Robotic Assistance in the Presurgical Evaluation of Medical Refractory Epilepsy: A Technical Note

Published on: June 13, 2016

Sampling Cerebrospinal Fluid and Blood from Lateral Tail Vein in Rats During EEG Recordings
10:46

Sampling Cerebrospinal Fluid and Blood from Lateral Tail Vein in Rats During EEG Recordings

Published on: September 1, 2023

Area of Science:

  • Neurology
  • Clinical Pharmacology
  • Epileptology

Background:

  • Inpatient video-EEG monitoring is crucial for epilepsy diagnosis and treatment.
  • Standardized antiseizure medication (ASM) tapering protocols are lacking across institutions.
  • Current protocols may lead to prolonged hospitalizations or increased risk of bilateral tonic-clonic seizures (BTCSs).

Purpose of the Study:

  • To investigate the influence of ASM taper strategies on length of stay (LOS) and patient outcomes in the epilepsy monitoring unit (EMU).
  • To develop evidence-based guidelines for optimizing ASM reduction to maximize diagnostic yield and minimize patient risk.
  • To identify predictors of BTCS risk and LOS during ASM tapering.

Main Methods:

  • Utilized natural language processing to extract data from 639 patient electronic medical records (2017-2023).
  • Estimated total ASM load using dose-dependent pharmacokinetic models.
  • Applied LASSO regression and mixed-effects models to analyze taper speed, ASM load, and BTCS risk.

Main Results:

  • Taper speed did not correlate with BTCS risk; absolute ASM load was a significant predictor.
  • Median ASM loads at seizure occurrence varied: 51% (history of BTCS), 41% (no history), 39% (unclear).
  • Longer LOS correlated with time to first seizure and number of baseline ASMs, not taper speed.

Conclusions:

  • Patient history of BTCS and ASM load are key predictors of BTCS risk.
  • Rapid tapering to ~50% baseline ASM load may efficiently precipitate seizures without increasing BTCS risk in patients without prior BTCS history.
  • Individualized ASM taper protocols are recommended, especially for severe epilepsies, to optimize EMU outcomes.